Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Chris Runken

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease|October 29, 2020
Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the USRobert Sandhaus, Charlie Strange, Glenda Stone, et al.
Headache|November 15, 2011
Examining the interrelationship of migraine onset, duration, and time to treatmentStephen H Landy, M Chris Runken, Christopher F Bell, et al.
Journal of Occupational and Environmental Medicine|December 29, 2010
Assessing the impact of migraine onset on work productivityStephen H Landy, M Chris Runken, Christopher F Bell, et al.
Journal of Medical Economics|April 24, 2018
Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United StatesEllis J Neufeld, Robert F Sidonio, Ken O'Day, et al.
Current Alzheimer Research|September 25, 2024
Post-Hoc Assessment of Cognitive Efficacy in Alzheimer's Disease Using a Latent Growth Mixture Model in AMBAR, a Phase 2B Randomized Controlled TrialNicolai D Ayasse, Walter F Stewart, Richard B Lipton, et al.
Journal of Diabetes and Its Complications|July 9, 2016
The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathyVera Bril, Christopher M Blanchette, Joshua M Noone, et al.
Headache|June 19, 2013
A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthyStephen H Landy, Ira M Turner, M Chris Runken, et al.
Applied Health Economics and Health Policy|October 9, 2014
Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USAM Chris Runken, Bridgett Goodwin, Manan Shah, et al.
Current Medical Research and Opinion|March 3, 2009
Estimating the prevalence and economic burden of overactive bladder among Medicare beneficiaries prior to Medicare Part D coverageMiriam G Cisternas, Aimee J Foreman, Thomas S Marshall, et al.
Headache|September 3, 2013
Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) studyRichard B Lipton, Daniel Serrano, Robert A Nicholson, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
International Journal of Chronic Obstructive Pulmonary Disease|October 29, 2020
Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the USRobert Sandhaus, Charlie Strange, Glenda Stone, et al.
Headache|November 15, 2011
Examining the interrelationship of migraine onset, duration, and time to treatmentStephen H Landy, M Chris Runken, Christopher F Bell, et al.
Journal of Occupational and Environmental Medicine|December 29, 2010
Assessing the impact of migraine onset on work productivityStephen H Landy, M Chris Runken, Christopher F Bell, et al.
Journal of Medical Economics|April 24, 2018
Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United StatesEllis J Neufeld, Robert F Sidonio, Ken O'Day, et al.
Current Alzheimer Research|September 25, 2024
Post-Hoc Assessment of Cognitive Efficacy in Alzheimer's Disease Using a Latent Growth Mixture Model in AMBAR, a Phase 2B Randomized Controlled TrialNicolai D Ayasse, Walter F Stewart, Richard B Lipton, et al.
Journal of Diabetes and Its Complications|July 9, 2016
The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathyVera Bril, Christopher M Blanchette, Joshua M Noone, et al.
Headache|June 19, 2013
A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthyStephen H Landy, Ira M Turner, M Chris Runken, et al.
Applied Health Economics and Health Policy|October 9, 2014
Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USAM Chris Runken, Bridgett Goodwin, Manan Shah, et al.
Current Medical Research and Opinion|March 3, 2009
Estimating the prevalence and economic burden of overactive bladder among Medicare beneficiaries prior to Medicare Part D coverageMiriam G Cisternas, Aimee J Foreman, Thomas S Marshall, et al.
Headache|September 3, 2013
Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) studyRichard B Lipton, Daniel Serrano, Robert A Nicholson, et al.
Pageof 4